会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3BETA-OL
    • 17-OXIMINO-5-ANDROSTEN-3BETA-OL的新型甾体酯
    • US20100292201A1
    • 2010-11-18
    • US12733415
    • 2008-08-14
    • Tilak Raj BhardwajManoj KumarNeelima DhingraNeeraj Mehta
    • Tilak Raj BhardwajManoj KumarNeelima DhingraNeeraj Mehta
    • A61K31/568C07J41/00A61P5/28A61P13/08
    • C07J41/0016
    • The present invention relates to steroidal esters of 17-oximino-5-androsten-3-ol, of compound of general formula (A) wherein R is selected from a group consisting of arylalkyl, aryl, substituted aryl. The ester derivatives are synthesized starting from Dehydroandrosterone acetate. The compounds were tested for their antiproliferative activity and 5α-reductase inhibitory activity in comparison to Finasteride. Decreased androgen level have been found in serum of animal treated with newly synthesized compounds. These compounds have also shown better cytotoxicity in comparison to reference drug Finasteride. Thus such compounds can be useful in treatment of androgen dependent disorder of prostate alone or by synergistic effect they can decrease the size of prostate due to their antiproliferative activity.
    • 本发明涉及通式(A)化合物,其中R选自芳烷基,芳基,取代芳基的17-肟基-5-雄甾-3-醇类甾体酯。 酯衍生物是从乙酸脱氢睾酮开始合成的。 与非那雄胺相比,测试了这些化合物的抗增殖活性和5α-还原酶抑制活性。 在新合成的化合物处理的动物血清中发现雄激素水平降低。 与参考药物非那雄胺相比,这些化合物也显示出更好的细胞毒性。 因此,这样的化合物可用于治疗前列腺单独的雄激素依赖性病症或通过协同作用,由于它们的抗增殖活性,它们可以减少前列腺的大小。